GlassScriptPhysician profile
Lauren Frankoff
NPI 1912414509
$9,754.35
in general payments reported to CMS, 2019-2025
25 companies · $2,771 in 2025
The $2,771 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,146 · 2022: $701 · 2023: $2,124 · 2024: $3,012 · 2025: $2,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,979 · Travel and Lodging: $929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,979.01 |
| Travel and Lodging | $929.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,171.22 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Janssen Pharmaceuticals, INC | $1,417.25 | 2021-2024 | Xarelto |
| Impulse Dynamics (USA) INC. | $1,296.39 | 2021-2025 | Optimizer, Optimizer |
| Amgen INC. | $566.29 | 2023-2025 | Repatha, Repatha |
| Abiomed | $371.00 | 2024-2025 | Impella |
| Merck Sharp & Dohme LLC | $242.53 | 2022-2025 | Verquvo |
| Astellas Pharma US INC | $235.46 | 2023 | Cresemba |
| Lexicon Pharmaceuticals, INC. | $192.63 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $165.84 | 2021-2024 | Farxiga |
| Heartflow, INC. | $151.38 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.21 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $118.20 | 2022-2023 | Eliquis |
| Daiichi Sankyo INC. | $115.22 | 2023 | Injectafer |
| Edwards Lifesciences Corporation | $86.19 | 2024-2025 | Pascal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.67 | 2021-2024 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $76.20 | 2021-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Novartis Pharmaceuticals Corporation | $61.43 | 2021-2025 | |
| Medtronic, INC. | $54.74 | 2023-2025 | Corevalve Evolut R |
| Cvrx, INC. | $54.70 | 2025 | Barostim Neo System |
| Boston Scientific Corporation | $54.13 | 2024-2025 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $26.43 | 2025 | Livtencity |
| Vifor Pharma, INC. | $23.13 | 2021 | |
| Bridgebio Pharma, INC. | $21.98 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $16.50 | 2023 | Arcalyst |
| Pfizer INC. | $14.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Frankoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.